Loss-of-function genetic diseases and the concept of pharmaceutical targets
2007
Challenges in Drug Development for Genetic Diseases
Commentary
Evidence: moderate
Author Information
Author(s): Ségalat Laurent
Primary Institution: CGMC, CNRS-UMR 5534, Université Lyon 1, France
Hypothesis
The target-based drug development model may not be suitable for most loss-of-function genetic diseases.
Conclusion
The concept of pharmaceutical targets is often vague for loss-of-function genetic diseases, complicating drug discovery efforts.
Supporting Evidence
- The target-based drug development model works well for gain-of-function diseases but poorly for most loss-of-function diseases.
- Loss-of-function diseases often have vague pharmaceutical targets, complicating treatment development.
- Investing in understanding the physiopathology of genetic diseases is crucial for future treatment strategies.
Takeaway
Finding treatments for genetic diseases is tricky because many of them don't have clear targets for drugs to work on. It's like trying to fix a toy without knowing how it works.
Limitations
The commentary discusses the limitations of applying a one-size-fits-all target-based approach to complex genetic diseases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website